12:00 AM
 | 
Apr 05, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DPX-0907: Phase I started

ImmunoVaccine began an open-label Phase I trial to evaluate 3 doses of 0.25 or 1 mL subcutaneous DPX-0907 given every 3 weeks...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >